Sarepta Therapeutics and Idera Pharmaceuticals are two bio-tech companies developing a drug to treat boys with Duchenne muscular dystrophy.
Sarepta Therapeutics' drug works by targeting the root cause of the disease whereas Idera Pharmaceuticals' drug focuses on the inflammation that causes muscle to degenerate.
Don Seiffert, an editor for the Boston Business Journal, joined NECN to discuss.
